Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velmanase alfa - Chiesi Farmaceutici

Drug Profile

Velmanase alfa - Chiesi Farmaceutici

Alternative Names: ALPHA-MAN project; Lamazym; Lamzede; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN

Latest Information Update: 25 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymenex A/S
  • Developer Chiesi Farmaceutici; Zymenex A/S
  • Class Mannosidases; Recombinant proteins
  • Mechanism of Action Alpha-mannosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha-Mannosidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alpha-Mannosidosis

Most Recent Events

  • 25 Jul 2019 Chiesi Farmaceutici plans the phase III SHAMAN trial for Alpha-Mannosidosis in USA, in January 2020 (NCT04031066)
  • 21 Feb 2019 Launched for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union, Norway, Iceland, Liechtenstein (IV) before February 2019
  • 04 Apr 2018 Registered for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union, Norway, Iceland, Liechtenstein (IV) - First Global Approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top